Observations placeholder
Letairis
Identifier
019253
Type of Spiritual Experience
Number of hallucinations: 40
Background
A description of the experience
Ambrisentan (U.S. trade name Letairis; E.U. trade name Volibris; is a drug used in the treatment of pulmonary hypertension.
The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor (ETA) Ambrisentan significantly improved exercise capacity (6-minute walk distance) compared with placebo in two double-blind, multicenter trials (ARIES-1 and ARIES-2)
Ambrisentan was approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency, and designated an orphan drug, for the treatment of pulmonary hypertension.
On Jan, 06, 2017 79,416 people reported to have side effects when taking Letairis.
Among them, 40 people (0.05%) have Hallucination
Time on Letairis when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 33.33% | 66.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
On Dec, 21, 2015: 15,148 people reported to have side effects when taking Letairis. Among them, 2,995 people (19.77%) have Death.
Time on Letairis when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 11.96% | 30.98% | 15.78% | 17.75% | 23.43% | 0.10% | 0.00% |